Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1613 1615 1616 1617 1628 1672 3786
This examiner grants 60% of resolved cases
Kyung Sook Chang is an examiner in Tech Center 3700 and Art Unit 1613. The examiner has 803 resolved cases. This volume of resolutions provides a basis for analyzing the examiner's prosecution patterns. The data offers a view of how applications are examined within this specific technical unit and the examiner's consistency in decision-making.
The allowance rate is 60.4 percent. This percentage shows the frequency of grants for applications that reach a final resolution with this examiner. The median days to allowance is 988. This figure indicates the time from filing to the grant of a patent. Practitioners can use this duration to estimate the timeline for their own applications in this art unit and plan their intellectual property strategy accordingly.
The interview lift is 40.9 percent. This metric indicates that an interview is associated with a significant increase in the probability of an allowance. The positive lift suggests that verbal communication is a highly effective method for resolving rejections with this examiner. Applicants might prioritize scheduling an interview to address the examiner's concerns and potentially accelerate the path to a patent grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18909337 | RHEOLOGICAL SOLID COMPOSITION | Non-Final OA | The Procter & Gamble Company |
| 18755888 | Oral Care Compositions Comprising Hops Beta Acids | Final Rejection | The Procter & Gamble Company |
| 18681981 | AN EXTRACT OF LINUM USITATISSIMUM SEEDS | Non-Final OA | BASF SE |
| 18682551 | ACTIVE COMPOUND COMBINATIONS AND FUNGICIDE COMPOSITIONS COMPRISING THOSE | Non-Final OA | Bayer Aktiengesellschaft |
| 18873973 | SUNSCREEN COMPOSITION FOR LACTOBACILLUS AND S. EPIDERMIDIS PROTECTION ON SKIN | Non-Final OA | DSM IP Assets B.V. |
| 18874006 | SUNSCREEN COMPOSITION FOR LACTOBACILLUS AND S. EPIDERMIDIS PROTECTION ON SKIN | Non-Final OA | DSM IP Assets B.V. |
| 17593514 | MOUSSE PRODUCTS, METHODS AND DEVICES | Final Rejection | Honeywell International Inc. |
| 18681600 | COMPOSITION FOR GENERATING NITROGEN MONOXIDE | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18673481 | BIOCOMPATIBLE MATERIAL AND METHODS FOR MAKING AND USING THEREOF | Final Rejection | The Hong Kong University of Science and Technology |
| 18506757 | CONTACT LENS FOR PHOTODYNAMIC INACTIVATION OF GERMS, PRODUCT AND METHOD OF TREATING FUNGAL KERATITIS BY APPLYING THE SAME | Non-Final OA | NATIONAL CHENG KUNG UNIVERSITY |
| 18878955 | Emulsion With a Dialkyl Carbonate, Coconut Oil Esters, a Volatile Hydrocarbon-Based Oil and a Polyethylene Glycol Dipolyhydroxystearate Containing 30 Mol of Ethylene Oxide | Non-Final OA | L'OREAL |
| 18543860 | COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, SEMI-CRYSTALLINE POLYMER AND SCLEROGLUCAN GUM | Non-Final OA | L'OREAL |
| 18729995 | ORAL DOSAGE FORMS OF A THERAPEUTICALLY ACTIVE ACID-LABILE SALT AND METHODS AND USES RELATED THERETO | Non-Final OA | UMC Utrecht Holding B.V. |
| 19018111 | Medical Adhesives For Quick Release Of Antimicrobials | Non-Final OA | Avery Dennison Corporation |
| 18879427 | COSMETIC COMPOSITION | Non-Final OA | SHISEIDO COMPANY, LTD. |
| 18378720 | BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING MEDICAL PRODUCTS | Non-Final OA | HOLLISTER INCORPORATED |
| 18595636 | COSMETIC | Non-Final OA | SHIN-ETSU CHEMICAL CO., LTD. |
| 18012065 | Biosurfactant Formulations for Use in Skincare and Wound Treatment | Non-Final OA | Locus Solutions IPCo, LLC |
| 18037359 | TOPICAL SANITISING COMPOSITION COMPRISING MINIMAL AMOUNTS OF AN ANTIMICROBIAL LIPID | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 19067282 | DELIVERY OF SUSTAINED LOCAL AND SYSTEMIC IMMUNOMODULATION | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18596376 | SYNTHETIC TISSUE BARRIERS AND USES THEREOF | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17784598 | SYNTHETIC TISSUE BARRIERS AND USES THEREOF | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18000982 | PREVENTION, REDUCTION, OR AMELIORATION OF OLD PERSON SMELL | Non-Final OA | Firmenich SA |
| 18874081 | Lipid Nanoparticles and Production Method for Same | Non-Final OA | Kewpie Corporation |
| 18597717 | ORAL SOLID DOSAGE FORMS COMPRISING CANNABINOIDS | Final Rejection | Jazz Pharmaceuticals Research UK Limited |
| 18259836 | STABLE EFFICIENT COSMETIC PREPARATIONS | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17928003 | 3-HYDROXYBUTYRIC-ACID-CONTAINING OIL AND FAT COMPOSITION | Non-Final OA | OSAKA GAS CO., LTD. |
| 18692208 | ACTIVE INGREDIENT DELIVERY SYSTEM | Non-Final OA | OPES CORPORATION OY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy